What is RS Research?
Founded in 2015 and based in Turkey, RS Research is dedicated to advancing cancer treatment through innovative drug delivery platforms. The company focuses on creating nanomedicines designed to enhance therapeutic efficacy for patients battling various forms of cancer. Its clinical-stage development signifies a commitment to translating scientific breakthroughs into tangible patient benefits.
How much funding has RS Research raised?
RS Research has raised a total of $13.2M across 2 funding rounds:
Private Equity
$1.2M
Series A
$12M
Private Equity (2017): $1.2M with participation from ACT Venture Partners
Series A (2021): $12M led by GEN Ilaç, One life Ventures, and Eczacıbaşı Momentum
Key Investors in RS Research
ACT Venture Partners
ACT Venture Partners is a venture capital firm that invests in early stage deep-tech startups. ACT (Accelerating the Commercialization of Technology) Fund I is fully invested and has a portfolio of 16 deep tech startups. While ACT is generalist, specific attention were given to startups with AI, IoT, and Big Data/Analytics component. ACT’s investment team is comprised of 4 experienced professionals with diverse and international backgrounds in investment management, entrepreneurship, engineering, and R&D funding and management.
One life Ventures
One life Ventures is a company that operates in the Banking industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in Mountain View, California.
GEN Ilaç
Undisclosed investor participating in the funding round.
What's next for RS Research?
The recent major strategic investment, alongside its overall funding trajectory, positions RS Research for accelerated growth and the scaling of its operations. This capital infusion is expected to fuel further research and development, potentially enabling the company to advance its pipeline candidates through critical clinical trials and towards commercialization. The company's focus on novel nanomedicines suggests a strategic intent to capture a significant share of the oncology market.
See full RS Research company page
